Krystal microplate enables development of drug testing assay
Scientists at the NCBS using Krystal 384-well black microplates to produce a standard drug testing assay for Plasmodium vivax infection.
Porvair Sciences reports that the National Center for Biological Sciences (NCBS) in Bangalore, India is using its Krystal 384 black microplate to produce a standard drug testing assay for Plasmodium vivax infection.
The NCBS is a leading national institute whose faculty members undertake research in the frontier areas of biology. Scientists at the NCBS use experimental and computational approaches to study molecules, cells and organisms creating an understanding of the biology at each of these levels to advance an integrated view of life processes.
In their research, the NCBS is using Krystal 384-well black microplates as the micro-environment to grow the cells infected with small numbers of parasites. Researchers are then treating the Krystal 384 black plates with different concentrations of drugs to check the effect on the infection and the development of the Plasmodium vivax parasites inside the cells.
Dr Mulaka Maruthi, a senior NCBS researcher commented "Because they are manufactured to a very high flatness tolerance the Porvair Sciences Krystal 384-well black plates are very convenient to use with both our inverted microscope and High Content Screening machine. The clear plate bottom permits direct microscopic viewing or HCS imaging and the images are of high resolution". Dr Maruthi added "Using the Krystal 384-well black plates we have been able to minimize the number of cells for seeding, use smaller numbers of parasites, and lower volumes of drugs. Overall the Krystal 384 black plate has enabled us to perform these experiments in a single plate instead of many 96 well plates or other well formats".
The Krystal 384-well microplate range incorporates novel square wells with a large liquid capacity of 120µl per well, increasing the achievable sensitivity of most HTS assays. Using a proprietary manufacturing technique, the Krystal 384 offers market leading plate flatness (+/- 0.1mm tolerance) that translates into a significant increase in measurement precision and elimination of read errors when performing cell based assays using fluorescent or luminescent imaging. All tissue-culture treated plates are supplied lidded and sterile, in individual bags.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance